{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:10:58Z","timestamp":1760004658975,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jpba.2024.115962","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:12:32Z","timestamp":1704373952000},"page":"115962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma"],"prefix":"10.1016","volume":"240","author":[{"given":"Barend J.","family":"Sikkema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie G.J.","family":"Robbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.S.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jpba.2024.115962_bib1","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.94.21.11445","article-title":"Activating mutations for the met tyrosine kinase receptor in human cancer","volume":"94","author":"Jeffers","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1 Suppl","key":"10.1016\/j.jpba.2024.115962_bib2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"5","key":"10.1016\/j.jpba.2024.115962_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6","article-title":"Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family","volume":"82","author":"Olivero","year":"1999","journal-title":"Int J. Cancer"},{"issue":"14","key":"10.1016\/j.jpba.2024.115962_bib4","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","article-title":"Novel mutations of the MET proto-oncogene in papillary renal carcinomas","volume":"18","author":"Schmidt","year":"1999","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.jpba.2024.115962_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jpba.2024.115962_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.onc.1209057","article-title":"Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma","volume":"25","author":"Miller","year":"2006","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.jpba.2024.115962_bib7","first-page":"1143","article-title":"Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization","volume":"78","author":"Hara","year":"1998","journal-title":"Lab Invest"},{"issue":"9","key":"10.1016\/j.jpba.2024.115962_bib8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2217\/fon-2021-1406","article-title":"INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance","volume":"18","author":"FS","year":"2022","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.jpba.2024.115962_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5827","key":"10.1016\/j.jpba.2024.115962_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jpba.2024.115962_bib11","first-page":"539","article-title":"The current landscape for METex14 skipping mutations in non-small cell lung cancer","volume":"13","author":"Desai","year":"2022","journal-title":"J. Adv. Pr. Oncol."},{"issue":"10","key":"10.1016\/j.jpba.2024.115962_bib12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jpba.2024.115962_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.jpba.2024.115962_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.jpba.2024.115962_bib15","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-14-3258","article-title":"The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species-specific insoluble metabolite formation","volume":"21","author":"Lolkema","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.jpba.2024.115962_bib16","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1124\/dmd.118.081919","article-title":"Metabolism of c-Met kinase inhibitors containing quinoline by aldehyde oxidase, electron donating, and steric hindrance effect","volume":"46","author":"Zhang","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.jpba.2024.115962_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10637-012-9823-9","article-title":"Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET","volume":"31","author":"Infante","year":"2013","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.jpba.2024.115962_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.toxlet.2023.10.003","article-title":"SGX523 causes renal toxicity through aldehyde oxidase-mediated less-soluble metabolite formation in chimeric mice with humanized livers","volume":"388","author":"Uehara","year":"2023","journal-title":"Toxicol. Lett."},{"issue":"8","key":"10.1016\/j.jpba.2024.115962_bib19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.110.032375","article-title":"Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications","volume":"38","author":"Diamond","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.jpba.2024.115962_bib20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1158\/1078-0432.CCR-11-2503","article-title":"Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients","volume":"18","author":"Ciarimboli","year":"2012","journal-title":"Clin. Cancer Res"},{"issue":"16","key":"10.1016\/j.jpba.2024.115962_bib21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.4155\/fmc-2019-0183","article-title":"A primer of deuterium in drug design","volume":"11","author":"Cargnin","year":"2019","journal-title":"Future Med Chem."},{"key":"10.1016\/j.jpba.2024.115962_bib22","unstructured":"Bioanalytical Method Validation Guidance for Industry. Center for Drug Evaluation and Research. Food and Drug Administration (FDA); 2018. Report No.: FDA-2013-D-1020."},{"key":"10.1016\/j.jpba.2024.115962_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","article-title":"UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma","volume":"166","author":"Xu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.115962_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpba.2011.10.010","article-title":"Quantification of cabazitaxel in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry: a practical solution for non-specific binding","volume":"59","author":"de Bruijn","year":"2012","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:37:40Z","timestamp":1760002660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":24,"alternative-id":["S0731708524000025"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.115962","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.115962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115962"}}